Pyc Therapeutics Ltd has released a press release.
SRC Approves Dose Escalation in ADOA Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Story so far
Earlier from PYC Therapeutics
- Approval to Escalate Dosing in Kidney Disease Trial
- Presentation of Clinical Proof of Concept in Lead Program
- Completion of Entitlement Offer
- First Subject Dosed in PKD Clinical Trial
- Placement of Shortfall
Later from PYC Therapeutics
- FDA Alignment on Registrational Trial Design RP11 Program
- Fourth Drug Program Progressing to Human Trials
- Approval to Progress Kidney Disease Trial to Next Stage
- Approval to Escalate Dosing in Kidney Disease Clinical Trial
- Appendix 4E
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics